• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

The Path Forward: Navigating the DSCSA Stabilization Policy


Learn more about the ins and outs of the new DSCSA stabilization policy, delaying some facets of DSCSA implementation to November 2024.

Elizabeth Gallenagh, JD, general counsel and senior vice president of supply chain integrity at the Healthcare Distribution Alliance, Tish Pahl, JD, principal at Olsson Frank Weeda Terman Matz PC, and Scott Mooney, vice president of distribution operations at McKesson, discussed the FDA’s Drug Supply Chain Security Act (DSCSA) stabilization policy, which delays some facets of DSCSA implementation to November 2024.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.